Straits Times Index
3,306.02 +6.02 (+0.18%) S&P 500
5,464.62 -8.55 (-0.16%) Dow
39,150.33 +15.53 (+0.04%) Nasdaq
17,689.36 -32.24 (-0.18%) Bitcoin USD
64,082.49 -149.79 (-0.23%) CMC Crypto 200
1,322.54 -37.79 (-2.78%)
EDIT Jan 2026 2.500 call
| Previous close | 3.1000 |
| Open | 3.1000 |
| Bid | 3.0000 |
| Ask | 5.5000 |
| Strike | 2.50 |
| Expiry date | 2026-01-16 |
| Day's range | 3.1000 - 3.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 113 |
ZacksEditas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
GlobeNewswireEditas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%. Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA RUBY oral pres
- GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA EdiTHAL poster presentation on Friday, June 14 at 6 p.m. CEST/Noon EDT CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.
